Patents by Inventor Holger Monenschein

Holger Monenschein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES
    Publication number: 20230028114
    Abstract: Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein ?, ?, n, R4, R5, R6, R8, R9, R10, R11, X1, X2, X3 and X7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.
    Type: Application
    Filed: September 15, 2020
    Publication date: January 26, 2023
    Inventors: Holger MONENSCHEIN, Sean MURPHY, Scott OLSEN, Natasha O'ROURKE, Holly REICHARD, Melinda DAVIS, Betty LAM
  • Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6
    Patent number: 11426397
    Abstract: Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: August 30, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason Green, Maria Hopkins, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Holger Monenschein, Sean Murphy, Thomas Nixey, Huikai Sun
  • 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
    Patent number: 11173161
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: November 16, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • PIPERIDINYL- AND PIPERAZINYL-SUBSTITUTED HETEROAROMATIC CARBOXAMIDES AS MODULATORS OF GPR6
    Publication number: 20200375969
    Abstract: Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Application
    Filed: March 26, 2018
    Publication date: December 3, 2020
    Inventors: Jason Green, Maria Hopkins, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Holger Monenschein, Sean Murphy, Thomas Nixey, Huikai Sun
  • Substituted pyrido[3,4-b]pyrazines as GPR6 modulators
    Patent number: 10738046
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: August 11, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139
    Publication number: 20200129518
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Application
    Filed: January 2, 2020
    Publication date: April 30, 2020
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • Tetrahydropyridopyrazines as modulators of GPR6
    Patent number: 10597392
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 24, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Huikai Sun, Todd Macklin
  • 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
    Patent number: 10561662
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 18, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • Tetrahydropyridopyrazine modulators of GPR6
    Patent number: 10406157
    Abstract: Disclosed is a compound of Formula 1, and a pharmaceutically acceptable salt thereof. This disclosure also relates to materials and methods for preparing the compound of Formula 1, to pharmaceutical compositions which contain it, and to its use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: September 10, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • 5-HT3 receptor antagonists
    Patent number: 10407443
    Abstract: The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 10, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Todd Macklin, Maria Hopkins, Shota Kikuchi
  • TETRAHYDROPYRIDOPYRAZINES MODULATORS OF GPR6
    Publication number: 20190263801
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: November 30, 2018
    Publication date: August 29, 2019
    Inventors: Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Huikai Sun, Todd Macklin
  • Pyrazines as modulators of GPR6
    Patent number: 10273225
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: April 30, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Mark E. Adams, Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Betty Lam, Holger Monenschein, Holly Reichard, Huikai Sun
  • 4-OXO-3,4-DIHYDRO-1,2,3-BENZOTRIAZINE MODULATORS OF GPR139
    Publication number: 20190070187
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Application
    Filed: November 2, 2018
    Publication date: March 7, 2019
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • Tetrahydropyridopyrazines as modulators of GPR6
    Patent number: 10179783
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: January 15, 2019
    Assignee: Taketa Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Huikai Sun, Todd Macklin
  • 4-OXO-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
    Patent number: 10159677
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: December 25, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6
    Publication number: 20180360831
    Abstract: Disclosed is a compound of Formula 1, and a pharmaceutically acceptable salt thereof. This disclosure also relates to materials and methods for preparing the compound of Formula 1, to pharmaceutical compositions which contain it, and to its use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Application
    Filed: June 15, 2018
    Publication date: December 20, 2018
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • SUBSTITUTED PYRIDO[3,4-b]PYRAZINES AS GPR6 MODULATORS
    Publication number: 20180346464
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Application
    Filed: August 7, 2018
    Publication date: December 6, 2018
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • 5-HT3 RECEPTOR ANTAGONISTS
    Publication number: 20180327421
    Abstract: The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: July 23, 2018
    Publication date: November 15, 2018
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Todd Macklin, Maria Hopkins, Shota Kikuchi
  • 5-HT3 receptor antagonists
    Patent number: 10125145
    Abstract: The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: November 13, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Holger Monenschein, Holly Reichard, Huikai Sun, Shota Kikuchi, Todd Macklin, Maria Hopkins
  • Substituted pyrido[3,4-b]pyrazines as GPR6 modulators
    Patent number: 10077266
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: September 18, 2018
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin